Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Investors & media

Direct access
  • Company Overview
  • Financial press releases
  • Events & presentations
  • Stock information & Financial agenda
  • Governance
  • Documentation
  • Home >
  • Investors & media

This information is intended for investors and the financial community

In this section, we provide investors and the media with pertinent regulatory and financial information as well as news and announcements about the company’s activities

© 2023 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page